ECM-targeting agents such as hyaluronidase and collagenase further dismantle fibrotic networks, as demonstrated in BC models where tranilast (a TGF-β inhibitor) combined with Doxil reduces ECM stiffness, improves vessel perfusion, and boosts anti-PD1 efficacy [365]. Here, TGFB1 is linked to breast cancer.